NRC Health shares have declined 8.3% since reporting second-quarter 2026 results, even as adjusted net income rose to 31 cents per share from 28 cents a year earlier and total recurring contract value climbed 11% to $151.9 million. Revenue increased 4% to $35.4 million, while GAAP net loss widened to $3.3 million from $0.1 million due to higher operating expenses including executive transition costs and stock compensation. Adjusted EBITDA was $9.4 million, down from $10.3 million, and management noted that reported revenue growth faced a roughly two-percentage-point headwind from an accounting change. The company declared a quarterly dividend of 16 cents per share and repurchased about 397,000 shares under its $60 million authorization.
National Research CorpShares fell 8.3% despite higher EPS and TRCV growth, with widened GAAP loss and lower adjusted EBITDA.